Example: Heart Attack

Search clinical trials for: Dasatinib

Total 326 results

NCT03216070

Unknown status

Low-dose Dasatinib as First-line Treatment for Chronic Myeloid Leukemia

Conditions: Chronic Myelogenous Leukemia
NCT04115059

Recruiting

Dasatinib In Waldenström Macroglobulinemia

Conditions: Waldenstrom Macroglobulinemia; DASATINIB
NCT04155411

Recruiting

Dose Reduced Dasatinib (70 mg Daily) as First-line Treatment for Newly Diagnosed CML-CP

Conditions: Dasatinib; BCR-ABL; Chronic Myeloid Leukemia
NCT01724879

Completed

Study of Frontline Dasatinib Plus Chemotherapy in Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (PH+ALL)

Conditions: Philadelphia Positive Acute Lymphoblastic Leukemia
NCT03625388

Recruiting

Low Dose Dasatinib (50 mg Daily) as First-line Treatment for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia

Conditions: Chronic Myelogenous Leukemia
NCT04439305

Withdrawn

Testing Dasatinib as a Potential Targeted Treatment in Cancers With DDR2 Genetic Changes (MATCH-Subprotocol X)

Conditions: Advanced Lymphoma; Advanced Malignant Solid Neoplasm; Hematopoietic and Lymphoid Cell Neoplasm; Refractory Lymphoma; Refractory Malignant Solid Neoplasm; Refractory Plasma Cell Myeloma
NCT01609816

Terminated

Dasatinib for Modulating Immune System After Autologous Stem Cell Transplants for Multiple Myeloma, Non-Hodgkin, or Hodgkin Lymphoma

Conditions: Non-Hodgkin's Lymphoma; Multiple; Mycosis Fungoides; Hodgkin's Lymphoma; Multiple Myeloma
NCT01051115

Unknown status

Dasatinib Combination for Chronic Lymphocytic Leukemia(CLL) With Refractory Disease

Conditions: Chronic Lymphocytic Leukemia
NCT03560908

Withdrawn

Dasatinib Combined With Chemotherapy in Relapsed t(8;21) Acute Myeloid Leukemia With KIT D816 Mutation

Conditions: Relapsed AML; T(8;21); C-KIT Mutation
NCT03193281

Recruiting

KISS Study: Kinase Inhibition With Sprycel Start up

Conditions: Chronic Myeloid Leukemia
NCT02268370

Active, not recruiting

Treatment-free Remission Accomplished With Dasatinib in Patients With CML

Conditions: Chronic Myeloid Leukemia
NCT02428855

Completed

Phase II Trial of Dasatinib in Patients With Isocitrate Dehydrogenase (IDH)-Mutant Advanced Intrahepatic Cholangiocarcinoma

Conditions: Cholangiocarcinoma
NCT02389972

Completed

Effectiveness of Dasatinib in Adult Patients With Chronic Myeloid Leukemia in China: A Multicenter, Registry Study

Conditions: Leukemia, Myelogenous, Chronic, BCR-ABL Positive
NCT01850004

Active, not recruiting

Open-Label Study Evaluating Dasatinib Therapy Discontinuation in Patients With Chronic Phase Chronic Myeloid Leukemia With Stable Complete Molecular Response

Conditions: Chronic Phase Chronic Myeloid Leukemia
NCT01491633

Terminated

Dasatinib in Advanced Squamous Cell Lung Cancer

Conditions: Squamous Cell Lung Cancer
NCT00858403

Terminated

Dasatinib in Advanced Non-small Cell Lung Cancer (NSCL) With Ex Vivo and In Vivo Assessment of Tumor Target Modulation

Conditions: Lung Cancer
NCT00429949

Completed

A Phase II Study of Dasatinib in the Treatment of Relapsed or Plateau Phase Multiple Myeloma

Conditions: Relapsed, Refractory or Plateau Phase Multiple Myeloma
NCT00700882

Active, not recruiting

Dasatinib in Treating Patients With Locally Advanced or Metastatic Mucosal Melanoma, Acral Melanoma, or Vulvovaginal Melanoma That Cannot Be Removed By Surgery

Conditions: Melanoma (Skin)
NCT00624585

Completed

Study of Oral Dasatinib in Subjects With Myelodysplastic Syndrome (MDS) and Excess Marrow Blasts

Conditions: Myelodysplastic Syndromes
NCT01643603

Terminated

Dasatinib for Immune Modulation After Donor Stem Cell Transplant for Hematologic Malignancies

Conditions: Non-Hodgkin's Lymphoma; Hodgkin's Lymphoma; Myeloid Leukemia; Multiple Myeloma; Myelodysplastic Syndrome; Lymphoid Leukemia
NCT00652574

Unknown status

Dasatinib in Resectable Malignant Pleural Mesothelioma

Conditions: Malignant Pleural Mesothelioma
NCT01342679

Completed

A Study of Complete Molecular Response for Chronic Myeloid Leukemia in Chronic Phase Patients, Treated With Dasatinib

Conditions: Chronic Myeloid Leukemia
NCT01310010

Unknown status

Study of Dasatinib to Treat Philadelphia Positive Acute Lymphoblastic Leukemia

Conditions: Leukemia, Lymphoblastic, Acute, Philadelphia-Positive
NCT00787267

Terminated

Phase II Study of Dasatinib in Previously Treated Patients With Advanced NSCLC

Conditions: Non Small Cell Lung Cancer
NCT01916785

Completed

OPTIM DASATINIB (Optimized Tyrosine Kinase Inhibitors Monotherapy)

Conditions: Chronic Myelogenous Leukemia, BCR/ABL Positive